Maria Habel
Universidade Federal da Fronteira Sul(BR)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, Complement system in diseases, SARS-CoV-2 and COVID-19 Research, Hidradenitis Suppurativa and Treatments, Long-Term Effects of COVID-19
Most-Cited Works
- → Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys(2014)86 cited
- → Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?(2018)79 cited
- → Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition(2017)52 cited
- → Early Intra-Articular Complement Activation in Ankle Fractures(2014)24 cited
- → Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial(2022)16 cited
- → Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients(2023)8 cited
- → Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target(2021)3 cited
- → Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study(2023)2 cited
- → Complement in hidradenitis suppurativa(2018)
- → Controlling complement 5a (C5a) in disease setting requires a specifically targeted inhibition(2018)